Videos

Vodcast: Avacta Group Open Day 2022

3 November 2022

Clinical stage oncology company Avacta Group has moved its Therapeutics division to a new headquarters at Scale Space in Imperial College’s White City Campus, London. DDW Multimedia Editor Megan Thomas attended the open day to learn more about the company’s intentions. In this video, she speaks to Neil Bell, Chief Development Officer at Avacta and […]

Video: Solving your issues with fragmented supply chains, failed projects and disjointed services

1 October 2022

Securing life sciences supply chains – where chemistry meets biology and products meet services. Biosynth is at the edge of innovation. With an unrivalled research product portfolio and end-to-end manufacturing services, we are science led and customer focused to solve problems and deliver key reagents across complex chemicals, peptides and key biologics all from one […]

Listicle: Maximising outsourcing models beyond time and cost

28 September 2022

Challenges in outsourcing drug discovery In this listicle, SAMDITech outlines the benefits of outsourcing models in the pharmaceutical industry, looking past perceived costs to the value outsourcing can bring.   The goal of drug discovery is clear: Identify the most promising leads in the shortest amount of time. Many companies have several projects ongoing simultaneously, […]

Listicle: Selecting the best gene delivery method

7 June 2022

 Mirus Bio outlines when to use transfection reagents, viral transduction or electroporation   No single delivery method is ideal for all situations, but researchers may routinely employ a suboptimal approach for the sake of familiarity or to avoid any start-up costs associated with new methods.   The uses of nucleic acid delivery have expanded from recombinant […]

Listicle: Driving production in biologics with automation 

4 May 2022

Drug development technology has evolved rapidly in recent years, and with the industry advancement comes an increased capability of producing high-quality targeted large molecule drugs such as biologics and biosimilars. The significance of biologics is far-reaching, including treatment of rheumatologic diseases, cancer, diabetes and anaemia. The range of therapy modalities is ever-expanding and at present […]

Listicle: Lithuania’s biotechnology growth strategy

3 March 2022

Lithuania is dedicating time and resources establishing itself as a life science and biotechnology hub of excellence. DDW’s Megan Thomas analyses four pillars of Lithuania’s growth strategy, which involves ensuring female scientists take leading roles in industry, focusing on investment, developing a strong talent pool as well establishing itself as a go-to destination for clinical trials. […]

PerkinElmer Informatics helps chemists gain insights into structure and sequence activity 

1 February 2022

Signals Inventa is a next-generation data management system for the analysis of scientific results. PerkinElmer has released a video that explains how this platform works.   The video shares how Signals Inventa provides a faster way to help chemists gain insights into structure and sequence activity relationships through a guided search and analysis workflow that […]

Developing pain medication with fewer side effects 

3 December 2021

Dr. Ken Ng, a professor at the University of Windsor and adjunct professor at the University of Calgary (UCalgary), and Sam Carr, a PhD student from UCalgary, have been working with Dr. Peter Facchini’s group at UCalgary to better understand how natural opiates are produced. The team has narrowed their focus on one enzyme in the last stage of […]

Closing drug development gaps with new clinical prediction AI 

1 December 2021

Quris, an artificial intelligence (AI) company in the pharmaceutical industry, has launched a clinical prediction AI platform to predict which drug candidates will safely work in humans. This will improve efficacy and cut drug development costs.   What do they do?  Quris uses AI-powered miniaturised “patients-on-a-chip” to avoid the risks and costs of failed clinical trials and eliminate […]

Listicle: Experts on the differences between FDA and EMA regulations

6 October 2021

Biotechs involved in drug discovery have to navigate increasingly complex regulatory environments across borders. Experienced experts and non-executive advisors to Arriello, Eric Caugant, Principal Consultant at Pharmacovigilance Systems Consulting & Board advisor to Arriello, and Judi Sills, JM Sills Consulting & Board advisor to Arriello, highlight the main differences between US and EU requirements, and advise on […]

Next »